CN107646036B - 可用作5-脂氧合酶激活蛋白(flap)抑制剂的吡唑衍生物 - Google Patents
可用作5-脂氧合酶激活蛋白(flap)抑制剂的吡唑衍生物 Download PDFInfo
- Publication number
- CN107646036B CN107646036B CN201680029387.0A CN201680029387A CN107646036B CN 107646036 B CN107646036 B CN 107646036B CN 201680029387 A CN201680029387 A CN 201680029387A CN 107646036 B CN107646036 B CN 107646036B
- Authority
- CN
- China
- Prior art keywords
- methyl
- reaction mixture
- pyrazol
- etoac
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
- C07D231/50—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562156424P | 2015-05-04 | 2015-05-04 | |
| US62/156424 | 2015-05-04 | ||
| PCT/EP2016/059848 WO2016177703A1 (en) | 2015-05-04 | 2016-05-03 | Pyrazole derivatives useful as 5-lipoxygenase activating protein (flap) inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107646036A CN107646036A (zh) | 2018-01-30 |
| CN107646036B true CN107646036B (zh) | 2020-05-19 |
Family
ID=55910253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680029387.0A Active CN107646036B (zh) | 2015-05-04 | 2016-05-03 | 可用作5-脂氧合酶激活蛋白(flap)抑制剂的吡唑衍生物 |
Country Status (38)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR104512A1 (es) | 2015-05-04 | 2017-07-26 | Astrazeneca Ab | Compuestos de pirazol inhibidores de proteína activadora de 5-lipoxigenasa (flap) |
| CN109890385B (zh) * | 2016-10-28 | 2022-08-02 | 阿斯利康(瑞典)有限公司 | (1r,2r)-2-[4-(3-甲基-1h-吡唑-5-基)苯甲酰基]-n-(4-氧代-4,5,6,7-四氢吡唑并[1,5-a]吡嗪-3-基)环己烷甲酰胺的结晶形式 |
| GB201905721D0 (en) | 2019-04-24 | 2019-06-05 | Univ Dundee | Compounds |
| CN110169969B (zh) * | 2019-06-28 | 2022-05-27 | 南京医科大学 | Mk571在制备预防和治疗心脏病药物中应用 |
| CN111084775A (zh) * | 2020-02-17 | 2020-05-01 | 牡丹江医学院 | 一种用于治疗癫痫的药物组合物 |
| CN111419800B (zh) * | 2020-04-23 | 2021-03-19 | 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 | 用于治疗红斑狼疮的药物制剂及其制备方法 |
| CN111643498B (zh) * | 2020-07-20 | 2021-05-07 | 黑龙江中医药大学 | 一种治疗肾结石的药物组合物及其用途 |
| CN111714499B (zh) * | 2020-07-27 | 2021-05-11 | 黑龙江中医药大学 | 一种用于治疗多囊卵巢综合征的药物组合物 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005023818A2 (en) * | 2003-09-10 | 2005-03-17 | Gpc Biotech Ag | Heterobicyclic compounds as pharmaceutically active agents |
| CN101484442A (zh) * | 2006-05-02 | 2009-07-15 | 阿斯利康(瑞典)有限公司 | 用于治疗疼痛、阿尔茨海默氏病和精神分裂症的毒蕈碱性受体激动剂 |
| CN101652137A (zh) * | 2007-02-08 | 2010-02-17 | 阿斯利康(瑞典)有限公司 | β-2肾上腺素受体拮抗性的苯并噻唑酮的组合 |
| CN101686980A (zh) * | 2007-04-20 | 2010-03-31 | 先灵公司 | 四氢吡啶并[4,3-d]嘧啶酮衍生物及其使用方法 |
| CN101686983A (zh) * | 2007-05-10 | 2010-03-31 | Amr科技公司 | 芳基和杂芳基取代的四氢苯并-1,4-二氮杂䓬及其阻断去甲肾上腺素、多巴胺和5-羟色胺重摄取的用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP9400632A0 (en) | 1993-04-29 | 1995-10-07 | Zeneca Ltd | Ether derivatives. |
| US5773422A (en) | 1996-01-29 | 1998-06-30 | Komer; Gene | Avermectin formulation |
| GB2431927B (en) | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
| JP2010518025A (ja) | 2007-02-05 | 2010-05-27 | アミラ ファーマシューティカルス，インコーポレーテッド | ５−リポキシゲナーゼ活性化タンパク質（ｆｌａｐ）インヒビターとしての逆インドール |
| WO2009045700A2 (en) | 2007-10-05 | 2009-04-09 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| AR104512A1 (es) * | 2015-05-04 | 2017-07-26 | Astrazeneca Ab | Compuestos de pirazol inhibidores de proteína activadora de 5-lipoxigenasa (flap) |
-
2016
- 2016-05-03 AR ARP160101257A patent/AR104512A1/es active IP Right Grant
- 2016-05-03 PL PL19199606T patent/PL3670499T3/pl unknown
- 2016-05-03 HU HUE19199606A patent/HUE056875T2/hu unknown
- 2016-05-03 US US15/571,291 patent/US10183947B2/en active Active
- 2016-05-03 RS RS20191604A patent/RS59671B1/sr unknown
- 2016-05-03 HU HUE16720116A patent/HUE047445T2/hu unknown
- 2016-05-03 EA EA201792341A patent/EA032221B1/ru not_active IP Right Cessation
- 2016-05-03 PE PE2017002308A patent/PE20180247A1/es unknown
- 2016-05-03 EP EP16720116.9A patent/EP3292105B1/en active Active
- 2016-05-03 JP JP2017555792A patent/JP6564062B2/ja active Active
- 2016-05-03 SG SG11201708558RA patent/SG11201708558RA/en unknown
- 2016-05-03 HR HRP20192172TT patent/HRP20192172T1/hr unknown
- 2016-05-03 SM SM20210722T patent/SMT202100722T1/it unknown
- 2016-05-03 CR CR20170513A patent/CR20170513A/es unknown
- 2016-05-03 SM SM20190691T patent/SMT201900691T1/it unknown
- 2016-05-03 SI SI201631428T patent/SI3670499T1/sl unknown
- 2016-05-03 MY MYPI2017704101A patent/MY186647A/en unknown
- 2016-05-03 TW TW105113757A patent/TWI718146B/zh active
- 2016-05-03 SI SI201630537T patent/SI3292105T1/sl unknown
- 2016-05-03 ES ES19199606T patent/ES2902139T3/es active Active
- 2016-05-03 RS RS20211559A patent/RS62729B1/sr unknown
- 2016-05-03 PL PL16720116T patent/PL3292105T3/pl unknown
- 2016-05-03 ES ES16720116T patent/ES2760466T3/es active Active
- 2016-05-03 PT PT167201169T patent/PT3292105T/pt unknown
- 2016-05-03 PT PT191996065T patent/PT3670499T/pt unknown
- 2016-05-03 KR KR1020177034920A patent/KR102623474B1/ko active Active
- 2016-05-03 AU AU2016258874A patent/AU2016258874B2/en active Active
- 2016-05-03 EP EP19199606.5A patent/EP3670499B1/en active Active
- 2016-05-03 MX MX2017013571A patent/MX372755B/es active IP Right Grant
- 2016-05-03 DK DK16720116T patent/DK3292105T3/da active
- 2016-05-03 LT LTEP19199606.5T patent/LT3670499T/lt unknown
- 2016-05-03 WO PCT/EP2016/059848 patent/WO2016177703A1/en not_active Ceased
- 2016-05-03 CA CA2983668A patent/CA2983668C/en active Active
- 2016-05-03 HR HRP20211993TT patent/HRP20211993T1/hr unknown
- 2016-05-03 ME MEP-2019-358A patent/ME03663B/me unknown
- 2016-05-03 TN TNP/2017/000458A patent/TN2017000458A1/en unknown
- 2016-05-03 BR BR112017022757-6A patent/BR112017022757B1/pt active IP Right Grant
- 2016-05-03 CN CN201680029387.0A patent/CN107646036B/zh active Active
- 2016-05-03 DK DK19199606.5T patent/DK3670499T3/da active
-
2017
- 2017-10-16 IL IL255069A patent/IL255069B/en active IP Right Grant
- 2017-10-18 GT GT201700220A patent/GT201700220A/es unknown
- 2017-10-19 CL CL2017002660A patent/CL2017002660A1/es unknown
- 2017-10-20 DO DO2017000244A patent/DOP2017000244A/es unknown
- 2017-10-20 SV SV2017005549A patent/SV2017005549A/es unknown
- 2017-11-09 CO CONC2017/0011506A patent/CO2017011506A2/es unknown
- 2017-11-21 PH PH12017502112A patent/PH12017502112B1/en unknown
- 2017-12-01 ZA ZA2017/08189A patent/ZA201708189B/en unknown
-
2018
- 2018-11-20 US US16/196,217 patent/US10508119B2/en active Active
-
2019
- 2019-10-30 US US16/668,743 patent/US11001589B2/en active Active
- 2019-12-03 CY CY20191101268T patent/CY1122689T1/el unknown
-
2021
- 2021-04-22 US US17/237,656 patent/US11691978B2/en active Active
- 2021-12-23 CY CY20211101130T patent/CY1125179T1/el unknown
-
2023
- 2023-02-27 US US18/174,832 patent/US12024523B2/en active Active
-
2024
- 2024-05-21 US US18/670,264 patent/US20240317767A1/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005023818A2 (en) * | 2003-09-10 | 2005-03-17 | Gpc Biotech Ag | Heterobicyclic compounds as pharmaceutically active agents |
| CN101484442A (zh) * | 2006-05-02 | 2009-07-15 | 阿斯利康(瑞典)有限公司 | 用于治疗疼痛、阿尔茨海默氏病和精神分裂症的毒蕈碱性受体激动剂 |
| CN101652137A (zh) * | 2007-02-08 | 2010-02-17 | 阿斯利康(瑞典)有限公司 | β-2肾上腺素受体拮抗性的苯并噻唑酮的组合 |
| CN101686980A (zh) * | 2007-04-20 | 2010-03-31 | 先灵公司 | 四氢吡啶并[4,3-d]嘧啶酮衍生物及其使用方法 |
| CN101686983A (zh) * | 2007-05-10 | 2010-03-31 | Amr科技公司 | 芳基和杂芳基取代的四氢苯并-1,4-二氮杂䓬及其阻断去甲肾上腺素、多巴胺和5-羟色胺重摄取的用途 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107646036B (zh) | 可用作5-脂氧合酶激活蛋白(flap)抑制剂的吡唑衍生物 | |
| HK1208465A1 (en) | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b | |
| TW201838983A (zh) | Ask1抑制劑化合物及其用途 | |
| TW201422631A (zh) | 磺醯胺衍生物 | |
| EP3313833A1 (en) | Compounds and their use as inhibitors of n-myristoyl transferase | |
| CN115413279A (zh) | P2x3调节剂 | |
| US20110312941A1 (en) | 1,4-disubstituted piperidines as vasopressin receptor via antagonists | |
| CN113727973A (zh) | 可用作类法尼醇x受体调节剂的取代酰胺化合物 | |
| TWI881587B (zh) | 類木瓜蛋白酶(PLpro)抑制劑 | |
| WO2025051161A1 (zh) | 用于治疗或预防冠状病毒感染的3cl蛋白酶抑制剂及其用途 | |
| HK40085749A (en) | P2x3 modulators | |
| HK40013582A (en) | Ask1 inhibitor compounds and uses thereof | |
| HK1245255B (en) | Pyrazole derivatives useful as 5-lipoxygenase activating protein (flap) inhibitors | |
| NZ737672B2 (en) | Pyrazole derivatives useful as 5-lipoxygenase activating protein (flap) inhibitors | |
| HK1224663A1 (zh) | 取代的尿嘧啶及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |